

Amendments to th_ claims:

This listing of claims will replace all prior versions and listing of claims in the application:

Claim 128 (original): A method of treating cancer of the respiratory tract in a patient in need of treatment which comprises administering by inhalation a pharmaceutically safe and effective amount of an aerosolized vesicant anti-cancer agent; wherein said vesicant anti-cancer agent is unencapsulated.

Claim 129 (currently amended): A The method according to Claim 128 wherein said anti-cancer agent is selected from the group consisting of anthracyclines, alkylating agents, vinca alkaloids, and taxanes.

Claim 130 (currently amended): A The method according to Claim 128 129 wherein said anthracycline anti-cancer agent is selected from the group consisting of doxorubicin, epirubicin, daunorubicin, cyanomethylvinyl-doxorubicin cyanomorpholino-doxorubicin and idarubicin.

Claim 131 (currently amended): A The method according to Claim 129 151 wherein said alkylating agent anti-cancer agent is selected from the group consisting of mechlorethamine, mitomycin-C, dactinomycin, and mithramycin.

Claim 132 (withdrawn)

Claim 133 (withdrawn)

Claim 134 (withdrawn)

Claim 135 (currently amended): A The method according to Claim 128 wherein said vesicant anti-cancer agent is administered by inhalation as an aerosolized liquid, powder or gas.

Claim 136 (currently amended): A The method according to Claim 135 wherein said aerosolized vesicant anticancer agent is administered as an aerosolized liquid.

Claim 137 (currently amended): A The method according to Claim 135 wherein said aerosolized vesicant anthracycline is administered as an aerosolized powder.

Claim 138 (withdrawn)

Claim 139 (withdrawn)

Claim 140 (withdrawn)

Claim 141 (withdrawn)

Claim 142 (withdrawn)

Appl. No. 10/066,831
Amdt. dated 12/18/2003
Reply to Office Action of Sept. 22, 2003

Claim 143 (withdrawn)

Claim 144 (withdrawn)

Claim 145 (withdrawn)

Claim 146 (currently amended): A The method according to Claim 128 wherein the particle size of said aerosol is from about 0.1 μm to about 10.0 μm .

Claim 147 (currently amended): A The method according to Claim 146 wherein the particle size of said aerosol is from about 1.0 μm to about 5.0 μm .

Claim 148 (currently amended): A The method according to Claim 147 wherein the particle size of said aerosol is from about 2.0 μm to about 2.5 μm .

Claim 149 (withdrawn)

Claim 150 (canceled)

Claim 151 (new): The method according to Claim 129 wherein said anti-cancer agent is an alkylating agent.

Claim 152 (new): The method according to Claim 131 wherein said alkylating agent anti-cancer agent is mechlorethamine.

Claim 153 (new): The method according to Claim 131 wherein said alkylating agent anti-cancer agent is mitomycin-C.

Claim 154 (new): The method according to Claim 131 wherein said alkylating agent anti-cancer agent is dactinomycin.

Claim 155 (new): The method according to Claim 131 wherein said alkylating agent anti-cancer agent is mithramycin.

Claim 156 (new): The method according to Claim 131 wherein said vesicant anti-cancer agent is administered by inhalation as an aerosolized liquid.

Claim 157 (new): The method according to Claim 156 wherein said alkylating agent anti-cancer agent is dactinomycin.